Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 11/20 | 0.46 |
| ▸ | JAK3 | P52333 | 11/20 | 0.46 |
| ▸ | JAK1 | P23458 | 10/20 | 0.46 |
| ▸ | ADORA2A | P29274 | 6/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.38 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.36 |
| ▸ | MTOR | P42345 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1996420 | 0.86 | JAK2 (0.47) | JAK2JAK3JAK1ADORA2APIK3CA | |
| SCHEMBL16824620 | 0.86 | JAK2 (0.43) | JAK2JAK3JAK1ADORA2ACYP11B1 | |
| SCHEMBL12644096 | 0.84 | JAK2 (0.43) | JAK2JAK3JAK1ADORA2APIK3CA | |
| SCHEMBL1994455 | 0.84 | JAK2 (0.46) | JAK2JAK3JAK1ADORA2ACYP11B1 | |
| SCHEMBL2032583 | 0.83 | JAK2 (0.44) | JAK2JAK3JAK1CYP11B1CYP11B2 | |
| SCHEMBL2035111 | 0.83 | JAK2 (0.42) | JAK2JAK3JAK1ADORA2APIK3CA | |
| SCHEMBL1995017 | 0.82 | JAK2 (0.44) | JAK2JAK3JAK1CYP11B1CYP11B2 | |
| SCHEMBL15198118 | 0.81 | JAK2 (0.45) | JAK2JAK3JAK1ADORA2AALDH1A1 | |
| SCHEMBL2033332 | 0.81 | JAK2 (0.41) | JAK2JAK3JAK1ADORA2APIK3CA | |
| SCHEMBL12067354 | 0.81 | JAK2 (0.44) | JAK2JAK3JAK1ADORA2APIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | ALMIRALL, S.A. (ES) | 2013-04-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130089512-A1 | HETEROARYL IMIDAZOLONE DERIVATIVES AS JAK INHIBITORS | JAK2, JAK1, JAK3 | JAK2 1/4885JAK3 3/4885JAK1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.